Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Sold by US Bancorp DE

US Bancorp DE lowered its position in Denali Therapeutics Inc. (NASDAQ:DNLI) by 27.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,168 shares of the company’s stock after selling 448 shares during the quarter. US Bancorp DE’s holdings in Denali Therapeutics were worth $34,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. MONECO Advisors LLC lifted its holdings in Denali Therapeutics by 4.6% in the 3rd quarter. MONECO Advisors LLC now owns 9,100 shares of the company’s stock valued at $265,000 after purchasing an additional 400 shares in the last quarter. Integrated Advisors Network LLC acquired a new position in shares of Denali Therapeutics during the third quarter worth $283,000. China Universal Asset Management Co. Ltd. boosted its holdings in Denali Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 27,535 shares of the company’s stock valued at $802,000 after purchasing an additional 10,782 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Denali Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after acquiring an additional 920 shares in the last quarter. Finally, nVerses Capital LLC bought a new position in Denali Therapeutics during the 3rd quarter worth approximately $288,000. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the transaction, the director now directly owns 29,096 shares in the company, valued at approximately $844,656.88. The trade was a 50.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Vicki L. Sato sold 1,020 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $30.00, for a total transaction of $30,600.00. Following the sale, the director now owns 111,056 shares in the company, valued at $3,331,680. This trade represents a 0.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 86,578 shares of company stock valued at $2,474,440 over the last three months. 7.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Wedbush decreased their target price on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Raymond James reiterated a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. JPMorgan Chase & Co. lowered their price target on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Cantor Fitzgerald lowered Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th. Finally, Citigroup raised their price objective on Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.90.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock opened at $24.18 on Tuesday. Denali Therapeutics Inc. has a twelve month low of $14.56 and a twelve month high of $33.33. The firm has a market cap of $3.48 billion, a P/E ratio of -8.76 and a beta of 1.40. The firm’s 50-day simple moving average is $28.20 and its 200-day simple moving average is $24.09.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter in the prior year, the company posted ($0.72) EPS. On average, equities analysts forecast that Denali Therapeutics Inc. will post -2.69 earnings per share for the current fiscal year.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.